Attached files
| file | filename |
|---|---|
| EX-31.1 - EX-31.1 - CHINOOK THERAPEUTICS, INC. | adro-ex311_11.htm |
| EX-32.1 - EX-32.1 - CHINOOK THERAPEUTICS, INC. | adro-ex321_12.htm |
| EX-31.2 - EX-31.2 - CHINOOK THERAPEUTICS, INC. | adro-ex312_10.htm |
| EX-21.1 - EX-21.1 - CHINOOK THERAPEUTICS, INC. | adro-ex211_6.htm |
| EX-10.38 - EX-10.38 - CHINOOK THERAPEUTICS, INC. | adro-ex1038_1111.htm |
| EX-10.37 - EX-10.37 - CHINOOK THERAPEUTICS, INC. | adro-ex1037_1112.htm |
| EX-10.36 - EX-10.36 - CHINOOK THERAPEUTICS, INC. | adro-ex1036_1113.htm |
| EX-10.35 - EX-10.35 - CHINOOK THERAPEUTICS, INC. | adro-ex1035_1114.htm |
| EX-10.34 - EX-10.34 - CHINOOK THERAPEUTICS, INC. | adro-ex1034_1115.htm |
| EX-4.3 - EX-4.3 - CHINOOK THERAPEUTICS, INC. | adro-ex43_580.htm |
| 10-K - 10-K - CHINOOK THERAPEUTICS, INC. | adro-10k_20191231.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in Registration Statement Nos. 333-203508, 333-210016, 333-216373, 333-223382 and 333-229915 on Form S-8 and Registration Statement Nos. 333-219639 and 333-219640 on Form S-3 of our report dated March 9, 2020, relating to the consolidated financial statements of Aduro Biotech, Inc. and subsidiaries (the “Company”) appearing in this Annual Report on Form 10-K of the Company for the year ended December 31, 2019.
/s/ Deloitte & Touche LLP
San Francisco, California
March 9, 2020